[
    [
        {
            "time": "",
            "original_text": "财信证券给予金域医学推荐评级，常规业务增长迅速，业绩超预期，目标价格为117.00-136.50元",
            "features": {
                "keywords": [
                    "金域医学",
                    "推荐评级",
                    "常规业务",
                    "增长迅速",
                    "业绩超预期",
                    "目标价格"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "财信证券给予金域医学推荐评级，常规业务增长迅速，业绩超预期，目标价格为117.00-136.50元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]